Open access journal
|Article type||Research Paper*||Rapid Communication||Review paper (unsolicited)||Others|
|APC per article (USD $)||$2,500||$1,000||$1,250||0|
|APC per article (RMB Y)||Y16,250||Y6,500||Y8,125||0|
Production and Hosting by KeAi Communications Co., Ltd. on behalf of Chongqing Medical University, Chongqing, China. Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).
All articles published open access will be immediately and permanently free for everyone to read, download, copy and distribute.
A CC user license manages the reuse of the article. For articles accepted before and on March 15, 2023, permitted third party reuse is defined by CC BY-NC-ND. For articles accepted after March 15, 2023, CC BY license will be used and the following user license defines permitted third party reuse:
Creative Commons Attribution (CC BY):
Allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at https://creativecommons.org/licenses/by/4.0/
For open access publishing, this journal uses an exclusive licensing agreement. Authors will -retain copyright alongside scholarly usage rights, and KeAi Communications Co., Ltd. will be granted exclusive publishing and distribution rights.
This journal is published bimonthly (January, March, May, July, September and November).
Learn more about:
Journal Article Publishing Support Center